Mantle Cell Lymphoma (MCL) is a type of non-Hodgkin lymphoma that arises from B-cells in the lymph nodes. It is considered a rare and aggressive form of lymphoma, accounting for approximately 6% of all non-Hodgkin lymphoma cases.

MCL typically affects older adults, with a median age of diagnosis around 60 years old. It is more common in men than women. The characteristic feature of MCL is the overgrowth of cancerous B-cells in the mantle zone of the lymph node, hence the name "mantle cell lymphoma."

Symptoms of MCL can include painless swelling of lymph nodes, fatigue, night sweats, weight loss, and abdominal discomfort. Diagnosis is usually confirmed through a combination of imaging tests, blood tests, and a lymph node biopsy.

Treatment for Mantle Cell Lymphoma often involves a combination of chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, and sometimes radiation therapy. The choice of treatment depends on the stage of the disease, the individual's overall health, and other factors.

Prognosis for Mantle Cell Lymphoma varies depending on several factors, including the stage of the disease at diagnosis and the response to treatment. Despite being a challenging disease to treat, advancements in research and treatment options have improved outcomes for some patients with MCL.

It is essential for individuals diagnosed with MCL to work closely with a team of healthcare professionals, including oncologists, hematologists, and other specialists, to develop a personalized treatment plan and receive ongoing support throughout their journey with this type of lymphoma.